Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -386.36% | -73.63% | -172.57% | 237.27% | 110.06% |
| Total Depreciation and Amortization | 54.06% | 72.06% | 68.12% | 21.27% | 7.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.21% | -83.74% | -121.69% | 159.49% | -13.82% |
| Change in Net Operating Assets | -118.76% | -75.67% | 137.61% | -63.02% | -44.33% |
| Cash from Operations | -51.32% | -52.17% | 41.63% | 21.10% | -6.75% |
| Capital Expenditure | 81.08% | -290.63% | -2,550.00% | -1,425.00% | -131.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -270.34% | 17.08% | -528.13% | 78.53% | 22.74% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Investing | 44.50% | -390.78% | -283.46% | 72.64% | -403.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 72.19% | -362.99% | -24.56% | 91.47% | -121.09% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 64.72% | 34.95% | 38.42% | -13.61% | -16.02% |
| Cash from Financing | 70.47% | -262.42% | 482.98% | 70.57% | -82.78% |
| Foreign Exchange rate Adjustments | -156.67% | 427.27% | 328.36% | -477.50% | 176.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.31% | -557.67% | 625.08% | 113.00% | -139.82% |